Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Validation of a quantitative flow cytometer assay for monitoring HER-2/neu expression level in cell-based cancer immunotherapy products.

Randlev B, Huang LC, Watatsu M, Marcus M, Lin A, Shih SJ.

Biologicals. 2010 Mar;38(2):249-59. doi: 10.1016/j.biologicals.2009.12.001. Epub 2010 Jan 15.

PMID:
20080049
2.

Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties.

Arbetman AE, Lochrie M, Zhou S, Wellman J, Scallan C, Doroudchi MM, Randlev B, Patarroyo-White S, Liu T, Smith P, Lehmkuhl H, Hobbs LA, Pierce GF, Colosi P.

J Virol. 2005 Dec;79(24):15238-45.

3.

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.

Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, Sloan JA, Atherton P, Edmonson JH, Erlichman C, Randlev B, Wang Q, Freeman S, Rubin J.

Gene Ther. 2005 Mar;12(5):437-45.

PMID:
15647767
4.

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.

Nemunaitis J, Cunningham C, Tong A, Post L, Netto G, Paulson AS, Rich D, Blackburn A, Sands B, Gibson B, Randlev B, Freeman S.

Cancer Gene Ther. 2003 May;10(5):341-52.

PMID:
12719704
5.

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D.

Cancer Res. 2002 Nov 1;62(21):6070-9.

6.

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.

Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D.

Gene Ther. 2001 May;8(10):746-59.

7.
8.

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D.

J Clin Oncol. 2001 Jan 15;19(2):289-98.

PMID:
11208818
9.

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D.

Cancer Res. 2000 Nov 15;60(22):6359-66.

10.

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH.

Nat Med. 2000 Aug;6(8):879-85.

PMID:
10932224
11.

The effect of azelastine on neutrophil and eosinophil generation of superoxide.

Busse W, Randlev B, Sedgwick J.

J Allergy Clin Immunol. 1989 Feb;83(2 Pt 1):400-5.

PMID:
2563742
12.

Effect of nedocromil sodium on the beta-adrenergic response of human polymorphonuclear leucocytes.

Busse WW, Randlev B, Arbabian M, Ruoho A.

Drugs. 1989;37 Suppl 1:26-31; discussion 69-77. No abstract available.

PMID:
2547565

Supplemental Content

Loading ...
Support Center